After AstraZeneca's anti-covid vaccine, it is on that of Johnson & Johnson that Copenhagen is giving up.
The Danish health authority announced in a statement on Monday May 3 that it concluded "that the benefits of using the Johnson & Johnson Covid-19 vaccine do not outweigh the risk of causing a possible side effect, VITT (a very rare type of thrombosis associated with the injection of serum), in people who receive the vaccine ".
However, the European regulator and the World Health Organization (WHO) had both given the green light to the use of this single-dose viral vector vaccine within the European Union.
The European Medicines Agency (EMA) announced on April 20 that the blood clots identified in the United States should be listed as "very rare" side effects of the Johnson & Johnson vaccine against Covid-19, while estimating that the benefits outweigh the risks.
With AFP
The summary of the week
France 24 invites you to come back to the news that marked the week
I subscribe
Take international news everywhere with you!
Download the France 24 application
google-play-badge_FR